Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

ISRG Stock Trading at its Cheapest in 10 Years: Should You ... - sharewise

AI-generated analysis

📉 ISRG stock has declined over 40% from its January peak, trading at a forward P/E of 30.26X versus a 10-year median of 58.18X.

💰 Second-quarter 2026 revenue increased 19% year-over-year to $2.89 billion with adjusted EPS advancing 28%.

🔧 Total procedures rose 16%, with da Vinci procedures up 15% and Ion procedures jumping 36% to 48,000.

📈 Recurring revenue climbed 19% to $2.47 billion, now representing 85% of total revenue base.

🌍 International da Vinci procedures grew 20% in the quarter, with Europe and Asia each advancing 20%.

⚠️ Management forecasts U.S. procedure growth moderation due to ACA subsidy changes and obesity drug impacts.

🇨🇳 China faces competitive pressure and tender volume challenges affecting near-term international expansion.

💸 Gross margin outlook raised to 68-69% but elevated spending on freight, semiconductors, and depreciation expected.

🤖 Over 1,700 da Vinci 5 systems are installed with more than 100 planned updates rolling out globally.

📊 Single-port procedures increased 61% as the global installed base reached 445 systems.

🏥 ISRG lags the broader medical sector and its own industry peers over the past three months.

🔬 The company is progressing with ROSE and EBUS programs and submitted a next-gen flexible endoscope for FDA clearance.

Bullish Signals
  • Intuitive Surgical trades at a forward P/E of 30.26X, well below its 10-year median of 58.18X and historical high of 93.22X.
  • Second-quarter 2026 revenue increased 19% year-over-year to $2.89 billion while adjusted EPS advanced 28%.
  • Ion procedures jumped 36% in the quarter, surpassing 400,000 cumulatively and demonstrating rapid adoption.
  • International da Vinci procedures grew 20% in the second quarter, with Europe and Asia each advancing 20%.
  • Recurring revenue climbed 19% to $2.47 billion, representing a resilient 85% of total revenue base.
  • Management maintained its 2026 da Vinci procedure-growth forecast at 13.5-15.5%, expecting results toward the midpoint.
  • Single-port procedures increased 61% with a global installed base reaching 445 systems, showing strong platform traction.
Risk Factors
  • Investors are factoring in moderating U.S. procedure trends and competitive pressure in China affecting growth.
  • Higher freight costs, semiconductor-memory expenses, and faster growth of newer platforms create profitability pressure.
  • The stock has declined 15% over the past three months, lagging both its industry and the wider medical sector.
  • Obesity drug adoption is explicitly cited as a factor impacting surgical procedure volumes in the outlook.
  • European capital pressures and Japan's recovery timeline introduce uncertainty into international growth projections.
Full Analysis
Intuitive Surgical (ISRG) is trading at a forward 12-month P/E of 30.26X, significantly below its 10-year median of 58.18X and historical high of 93.22X, marking its cheapest valuation in a decade following a price decline exceeding 40%. Despite the steep multiple compression, the company maintains a 'D' Value Score, indicating it is not yet considered an outright bargain relative to the broader medical instruments industry average of 25.96X. Fundamental performance remains robust with second-quarter 2026 revenue rising 19% year-over-year to $2.89 billion and adjusted EPS advancing 28%. Total procedures increased 16%, driven by a 15% rise in da Vinci systems and a 36% surge in Ion procedures. Recurring revenue climbed to $2.47 billion, representing 85% of total revenue, while system utilization improved across both platforms. Management maintains its 2026 guidance for da Vinci procedure growth between 13.5% and 15.5%, citing international expansion as a key driver with 20% growth in Europe and Asia. However, the outlook incorporates near-term uncertainties including potential impacts from U.S. patient behavior changes, competitive pressures in China, European capital constraints, and the broader effects of obesity drug adoption on surgical volumes. While ISRG faces headwinds such as higher freight costs, semiconductor expenses, and elevated depreciation during platform transitions, its strong product pipeline offers a counterweight to concerns. The company has installed over 1,700 da Vinci 5 systems and is rapidly gaining traction with single-port procedures, which grew 61% in the quarter. Analysts suggest holding for existing investors while prospective buyers may wait for further evidence of accelerating growth before committing aggressively.